Endocrine Abstracts

Introduction: Lenvatinib is a multitarget tyrosine kinase inhibitor that has shown substantial efficacy in patients with progressive radioiodine refractory thyroid cancer (RAIRDTC) (progression free survival (PFS) 19.4 months and objective response rate 64.8%; SELECT trial) despite common adverse events (AEs).Objective: To evaluate efficacy and toxicity of lenvatinib treatment for RAIRDTC in daily clinical practice.Methods: Retrosp...

Aim: To assess survival rate and prognosis factors in a group of 65 patients with distant metastases from differentiated thyroid carcinoma.Methods: Patients with metastatic differentiated thyroid carcinoma (MDTC) were retrospectively identified from the database of a single institution (1975–2008). Disease-specific survival (DSS) was analyzed by the Kaplan-Meier method.Results: A total of 65 patients with MDTC were identified....

Aim: To analyze clinical features in a group of 65 patients with differentiated thyroid carcinoma and distant metastases.Methods: Retrospective review of 65 patients with Metastatic Differentiated Thyroid Carcinoma (MDTC) identified from the database of a tertiary hospital between 1975 and 2008.Results: Sixty five patients were identified (21 males, 44 females) with a mean age of 58,9 years. The median follow-up after discovery of ...

About 10–15% of prolactinomas (P) are resistant to Dopamine agonists (DA). We analyzed retrospectively ten resistant prolactinomas (RP) treated at our center between 1995 and 2014, to identify useful variables to predict DA resistance and its different patterns (biochemical resistance (BR), morphological resistance (MR) or both). BR is defined as the failure to normalize prolactin (PRL) levels with ≥ 2 mg/week of cabergoline (C) for at least 3 months. MR is consider...

Introduction: MTC accounts for 5% of thyroid cancers and can occur sporadically or as part of the multiple endocrine neoplasia type 2 syndrome (MEN 2). The objective of our study is to evaluate the prognostic factors and outcomes of patients with MTC in the community setting.Methods: Retrospective descriptive multicenter study of patients with histological diagnosis of MTC. Descriptive, bivariate analyses (Student t for cuantitative and ...

ATL1103 is a second generation antisense 20mer intended to inhibit expression of the GH receptor (GHR) gene. Phosphorothioate and 2′-O-methoxyethyl modifications to nucleotides increase its plasma half-life and affinity for the target RNA to allow post-hybridization RNaseH degradation. We previously reported a phase 2, randomised, open-label, parallel group study of ATL1103 in 26 patients with acromegaly which demonstrated a fall in serum IGF-I of 26% with 200 mg twice w...

ATL1103 is a second generation antisense oligomer directed at the GH receptor. It is a 20mer with a phosphorothioate backbone and 2′-O-methoxyethyl modifications of the five nucleotides at either end intended to increase its plasma half-life and affinity for the target RNA to allow post-hybridization RNaseH degradation. We report a phase 2 randomised, open-label, parallel group study of subcutaneously administered ATL1103 in patients with active acromegaly. Appr...

Background: Up to 15% of pheochromocytomas are malignant. The only definite criterion for malignancy is the presence of metastases. The histological differentiation between benign and malignant tumours is difficult, being a challenging problem nowadays.Aim: To asses if postoperative histological evaluation using the previously proposed pheochromocytoma of the adrenal gland scales scored (PASS) can predict malignancy.Methods: Twenty...

Introduction: This study aimed to determine the timeframe to achieve hormonal normalization considering dosing patterns of Somatuline Autogel (SOM, lanreotide) used in clinical practice.Methods: From March 2013 to October 2013 clinical data from 62 patients with active acromegaly treated with SOM for &gE;4 months who achieved hormonal control (GH levels <2.5 ng/ml and/or normalised IGF1 on &gE;two evaluations) at 17 Spanish hospitals were collected i...

Introduction: Endogenous Cushing’s syndrome (CS) is a rare, infradiagnosed and severe disease that carries high morbidity and mortality. Delays in treatment initiation reduce reversibility of symptoms and increase mortality rate. Current gold standard for screening, 24 h urinary free cortisol, has a low reproducibility and specificity, and sampling is complicated. Midnight salivary cortisol (MSVC) determination is considered an easy and cheap test. We intend to assess its...